ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 075,68
0,99%
Dow Jones
38 884,26
0,08%
DAX
18 430,05
1,42%
Brent Oil
82,915
-0,67%
Bitcoin
63 115,40
-0,08%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Opiant Pharmaceuticals Inc (OPNT)

  7. Opiant Pharmaceuticals Inc (OPNT) Actualités

OPNT

Opiant Pharmaceuticals (OPNT)

Opiant Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OPNT
DateHeureSourceTitreSymboleSociété
13/03/202311h16Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:OPNTOpiant Pharmaceuticals Inc
10/03/202312h05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202320h02Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202319h17Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202315h27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
27/02/202322h05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OPNTOpiant Pharmaceuticals Inc
16/02/202323h14Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
07/02/202322h01GlobeNewswire Inc.Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCNASDAQ:OPNTOpiant Pharmaceuticals Inc
06/02/202314h00GlobeNewswire Inc.Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLCNASDAQ:OPNTOpiant Pharmaceuticals Inc
19/01/202322h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
04/01/202322h21Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
21/12/202222h56Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
22/11/202222h01GlobeNewswire Inc.Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
15/11/202212h10Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202222h25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202210h26TipRanksHow Will Indivior’s $145M Purchase of Opiant Boost the Stock?NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202208h13GlobeNewswire Inc.Opiant Pharmaceuticals Announces Third Quarter 2022 Financial ResultsNASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202208h12GlobeNewswire Inc.Indivior PLC to Acquire Opiant PharmaceuticalsNASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202208h10PR Newswire (US)Indivior To Acquire Opiant PharmaceuticalsNASDAQ:OPNTOpiant Pharmaceuticals Inc
27/10/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/10/202214h01GlobeNewswire Inc.Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use DisorderNASDAQ:OPNTOpiant Pharmaceuticals Inc
22/08/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis SyndromeNASDAQ:OPNTOpiant Pharmaceuticals Inc
12/08/202213h30PR Newswire (Canada)MindMed Strengthens Board with Appointment of Two New Independent DirectorsNASDAQ:OPNTOpiant Pharmaceuticals Inc
11/08/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate UpdateNASDAQ:OPNTOpiant Pharmaceuticals Inc
08/08/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal NalmefeneNASDAQ:OPNTOpiant Pharmaceuticals Inc
02/08/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
01/08/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022NASDAQ:OPNTOpiant Pharmaceuticals Inc
28/06/202222h05GlobeNewswire Inc.Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
17/06/202222h54Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
08/06/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal NalmefeneNASDAQ:OPNTOpiant Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:OPNT

Dernières Valeurs Consultées

COIN
BTCUSD
Bitcoin
EU
GLE
Societe Generale
COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
EU
ACA
Credit Agricole
EU
CS
Axa
SPI
SP500
S&P 500
NYSE
NKE
Nike
EU
EN
Bouygues
NASDAQ
AMZN
Amazon.com
EU
RI
Pernod Ricard
EU
BEL20
Bel 20
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés